<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="82452">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02095548</url>
  </required_header>
  <id_info>
    <org_study_id>SM04690-01</org_study_id>
    <nct_id>NCT02095548</nct_id>
  </id_info>
  <brief_title>Phase 1, Dose Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SM04690 in Moderate to Severe Knee Osteoarthritis (OA)</brief_title>
  <official_title>A Phase 1, Placebo-Controlled, Double-Blind, Dose-Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SM04690 Injected in the Target Knee Joint of Moderately to Severely Symptomatic Osteoarthritis Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samumed LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samumed LLC</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find the optimal dose of SM04690 that can be safely given by
      intra-articular injection into the target knee joint of subjects with moderate to severe
      osteoarthritis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Safety assessments for this study will include adverse events, dose limiting toxicity (DLT), physical exams, vital signs, ECGs, and clinical laboratory tests</measure>
    <time_frame>during 24 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Additional safety assessment of bone loss as measured by CT of the knee</measure>
    <time_frame>during 24 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>The following PK parameters will be determined from the plasma of SM04690; Cmax, Tmax, AUC0-t, AUC0-âˆž, and t1/2</measure>
    <time_frame>during 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline pain over the last 48 hours using a Visual Analog Scale (VAS)</measure>
    <time_frame>during 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline per Western Ontario and McMaster Osteoarthritis (WOMAC) assessment of disease scale</measure>
    <time_frame>During 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline per physician global assessment of disease scale</measure>
    <time_frame>during 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in joint space width as measured by X-ray</measure>
    <time_frame>during 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of cartilage volume and thickness as measure by MRI</measure>
    <time_frame>during 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of biomarkers of cartilage synthesis and cytokines</measure>
    <time_frame>during 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Moderate to Severe Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>SM04690, 0.03mg/2mL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single, intra-articular injection of SM04690, 0.03mg/2mL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SM04690, 0.07mg/2mL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single, intra-articular injection of SM04690, 0.07mg/2mL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SM04690, 0.23mg/2mL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single, intra-articular injection of SM04690, 0.23mg/2mL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single, intra-articular injection of placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SM04690, 0.03mg/2mL</intervention_name>
    <arm_group_label>SM04690, 0.03mg/2mL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SM04690, 0.07mg/2mL</intervention_name>
    <arm_group_label>SM04690, 0.07mg/2mL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SM04690, 0.23mg/2mL</intervention_name>
    <arm_group_label>SM04690, 0.23mg/2mL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with primary OA in target knee by American College of Rheumatology (ACR)
             criteria

          -  Screening pain criteria sufficient as assessed by WOMAC and VAS scores

          -  Ability to read and understand the informed consent

        Exclusion Criteria:

          -  Women who are pregnant or lactating or child bearing potential, men must use a
             barrier method of contraception

          -  Any condition, including laboratory findings, that in the opinion of the investigator
             constitutes a risk or contraindication for participation in the study or that could
             interfere with the study objectives, conduct or evaluation

          -  Body mass index &gt;40

          -  Major knee surgery in the target knee within 12 months prior to study or planned
             surgery during the study period

          -  History of malignancy within the last 5 years

          -  Participation in a clinical research trial within 12 weeks prior

          -  Treatment of the target knee with intra-articular steroids within 2 months or
             hyaluronic acid derivatives within 6 months

          -  Effusion of the target knee requiring aspiration within 3 months

          -  Use of electrotherapy or acupuncture for OA within 4 weeks

          -  Significant and clinically evident misalignment of the target knee

          -  Any known active infections

          -  Any chronic condition that has not been well controlled for a minimum of 3 months
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nebojsa Skrepnik, MD, PhD</last_name>
      <phone>520-784-6140</phone>
      <email>nskrepnik@tucsonortho.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>El Cajon</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Louis Levy</last_name>
      <phone>619-334-4764</phone>
      <email>llevy@triwestresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Padaong</last_name>
      <phone>925-930-7267</phone>
      <email>jpadaong@diabloclinical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eddie Armas</last_name>
      <phone>305-665-4818</phone>
      <email>Drarmas@wpharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ellen Rosen</last_name>
      <phone>1-800-924-7790</phone>
      <phone_ext>224</phone_ext>
      <email>ellenrosen@altoonaresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Monday</last_name>
      <phone>214-424-0400</phone>
      <email>smonday@mcrcdallas.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>June 3, 2014</lastchanged_date>
  <firstreceived_date>March 18, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
